ReviewDrugs & aging2017
The Potential of β-Hydroxy-β-Methylbutyrate as a New Strategy for the Management of Sarcopenia and Sarcopenic Obesity.
Review in Drugs & aging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Ergogenic Benefits of β-Hydroxy-β-Methyl Butyrate (HMB) Supplementation on Body Composition and Muscle Strength: An Umbrella Review of Meta-Analyses.Journal of cachexia, sarcopenia and muscle · 2025Pooled it
- Effects of exercise with or withoutFrontiers in nutrition · 2024Pooled it
- Effects of Beta-Hydroxy-Beta-Methylbutyrate Supplementation on Older Adults with Sarcopenia: A Randomized, Double-Blind, Placebo-Controlled Study.The journal of nutrition, health & aging · 2023Trial
- Effects of β-Hydroxy β-Methylbutyric Supplementation in Combination with Conservative Non-Invasive Treatments in Athletes with Patellar Tendinopathy: A Pilot Study.International journal of environmental research and public health · 2022Trial
- Sarcopenia in the Aging Process: Pathophysiological Mechanisms, Clinical Implications, and Emerging Therapeutic Approaches.International journal of molecular sciences · 2025Review
- International society of sports nutrition position stand: β-hydroxy-β-methylbutyrate (HMB).Journal of the International Society of Sports Nutrition · 2025Review
- Dipalmitoylphosphatidylcholine Lipid Vesicles for Delivering HMB, NMN, and L-Leucine in Sarcopenia Therapy.Molecules (Basel, Switzerland) · 2025Article
- Lactoferrin combined with Coenzyme Q10 ameliorate sarcopenia in an aging mouse model induced by D-galactose.PloS one · 2025Article
- Muscle loss in cancer cachexia: what is the basis for nutritional support?Frontiers in pharmacology · 2025Review
- Article
- Age-Related Changes in Insulin Resistance and Muscle Mass: Clinical Implications in Obese Older Adults.Medicina (Kaunas, Lithuania) · 2024Review
- The Combination of Lactoferrin and Creatine Ameliorates Muscle Decay in a Sarcopenia Murine Model.Nutrients · 2024Article
- Relationship of endogenous plasma concentrations of β-hydroxy β-methyl butyrate (HMB) with frailty in community dwelling older adults with type-2 diabetes mellitus.The journal of nutrition, health & aging · 2024Article
- Interrelationship of Sarcopenia and Cardiovascular Diseases: A Review of Potential Mechanisms and Management.Journal of the ASEAN Federation of Endocrine Societies · 2024Review
- Age Is Just a Number: Progress and Obstacles in the Discovery of New Candidate Drugs for Sarcopenia.Cells · 2023Review
- Research progress in the role and mechanism of Leucine in regulating animal growth and development.Frontiers in physiology · 2023Review
- Identification of Preoperative Fat-Free Mass Index for the Prognosis of Curatively Resected Esophageal Cancer.World journal of surgery · 2022Article
- The role and therapeutic potential of stem cells in skeletal muscle in sarcopenia.Stem cell research & therapy · 2022Review
- Sarcopenia: Etiology, Nutritional Approaches, and miRNAs.International journal of molecular sciences · 2021Review
- How to Increase Muscle Mass in Critically Ill Patients: Lessons Learned from Athletes and Bodybuilders.Current nutrition reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is defined as an age-related loss of skeletal muscle mass and function and is recognized as a major clinical problem for older people. Essential amino acid supplementation, particularly β-hydroxy-β-methylbutyrate (HMB), a metabolite of leucine that is produced in skeletal muscle, has been evaluated in several studies as a nutritional approach to enhancing muscle protein synthesis in healthy or frail elderly subjects. Studies performed in in vitro conditions show that HMB may be effective in the treatment of muscle wasting, increasing myogenesis, reducing muscle apoptosis, and having a positive effect on muscle protein turnover; however, studies of the effects of HMB conducted in old animals have reported conflicting results. Clinical trials performed in older adults confirm that HMB can attenuate the progression of sarcopenia in elderly subjects. HMB supplementation results in an increase in skeletal muscle mass and strength in the elderly and its effect is even greater when combined with physical exercise. The role of HMB in sarcopenic obesity management is still under debate and a general lack of intervention studies in this population must be recognized. In conclusion, HMB appears to be effective for enhancing muscle mass and strength in the elderly. Less certain is the role of HMB supplementation in reducing fat mass and, thus, in the treatment of sarcopenic obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.